BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Company News  |  Deals

Optimer, Astellas deal

Optimer granted Astellas exclusive rights to develop and commercialize fidaxomicin in Europe and countries in the Middle East, Africa and the Commonwealth of Independent States (CIS)....

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >